PubNub Evolves Its Platform with AI-Native Development, Real-Time Moderation, and Decision Intelligence
PubNub, the leader in real-time interactive apps, unveiled the next evolution of its platform. It introduces AI-native development, real-time decision intelligence, and in-network content moderation to help developers build and scale faster while simplifying access to PubNub's full power.
The updates enable developers to build rich, real-time experiences like multiplayer games, collaborative tools, and healthcare apps with greater speed and control.
“The world expects real-time, intelligent experiences,” said Todd Greene, CEO, PubNub. “Our evolved platform brings AI, analytics, and moderation into the developer workflow, enabling safer, smarter apps with lower latency and greater impact.”
New Capabilities That Redefine Real-Time:
Generative AI Coding with MCP Server
PubNub’s new Model Context Protocol (MCP) Server connects large language models (LLMs) like those in AI-powered IDEs (e.g., Cursor, Windsurf) directly to live SDK knowledge. Developers can generate real-time features like chat, presence, or sync with a single prompt, without leaving their editor or searching documentation.
AI-Powered Auto-Moderation
BizOps Workspace offers built-in content filtering that runs in-cluster before messages are delivered to users. This serverless module scans messages for profanity, abuse, and spam in sub-500ms, with no external setup. Developers can apply preset rules or connect third-party tools, all from a no-code interface with no backend work.
Decision Intelligence with PubNub Illuminate & Insights
PubNub’s decisioning tools let teams monitor and optimize live applications with no-code dashboards, real-time anomaly detection, and automation rules. Product and engineering teams can optimize user flows, test changes, and respond to real-time behavior without redeploying.
“We’re closing the gap between ideation and execution,” said Stephen Blum, CTO, PubNub. “With generative coding, real-time decision engines, and in-network moderation, developers can build better apps faster and scale confidently.”
Why It Matters
- Accelerated development: AI tools reduce time-to-feature.
- Built-in safety: In-network moderation blocks harmful content.
- Live optimization: Adapt in real time.
- Enterprise-ready: Sub-100ms latency, 99.999% uptime, and full compliance (HIPAA, SOC 2, GDPR, ISO 27001).
About PubNub
PubNub powers real-time interactive experiences that drive engagement, retention, and monetization. Our platform enables over 2,000 companies to build, manage, and optimize apps that captivate users. Founded in 2012, PubNub is backed by investors like The Raine Group, Sapphire, Scale, Relay, Cisco, Bosch, Ericsson, and HPE. Start building at www.pubnub.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250611327297/en/
Contacts
Ben Stump
Ben.Stump@pubnub.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 Data for Incyte’s Retifanlimab (Zynyz ® ) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 01:45:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer (SCAC) who have not been previously treated with systemic chemotherapy, were published in The Lancet.1 “The publication of the POD1UM-303/InterAACT 2 trial in The Lancet is a testament to the strength of the data generated for retifanlimab in patients with inoperable locally recurrent or metastatic SCAC, a disease which until recently had seen limited innovation for decades,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “SCAC can be a devastating disease, and patients often have a poor prognosis. These data supported the U.S. Food and Drug Administration (FDA) approval of Zynyz® (retifanl
Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 22:30:00 EEST | Press release
Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal, but a core driver of innovation. Key milestones include a near-complete transition to natural refrigerants
Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 21:45:00 EEST | Press release
Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of European enterprises, providing a framework for high performance in even the most complex, secure environments. “With about 6 million developers across Europe, users deserve infrastructure that meets them where they are,” said Varun Mohan, CEO of Windsurf. “The demand for secure AI-powered development is undeniable and by launching this GPU cluster, we aim to b
Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 20:00:00 EEST | Press release
Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization journey, allowing developers to focus on building engaging games, not commerce infrastructure. This SDK connects three
Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 18:00:00 EEST | Press release
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom